CREDENCE

Canagliflozin and Renal Events in Diabetes with Established Nephropathy

Patient / Population Intervention / Exposure Comparison Outcome

In 4,401 patients with type 2 diabetes and albuminuric CKD on maximal RAS blockade, canagliflozin reduced the composite of ESKD, creatinine doubling or renal/CV death compared with placebo.

4,401

Design

Double-blind RCT, stopped early

Endpoint

ESKD, doubling of creatinine, or renal or CV death

Relevance

ResultHR 0.70 (95% CI 0.59–0.82; p<0.001); heart-failure hospitalisation HR 0.61.

Perkovic V, et al. N Engl J Med. 2019;380(24):2295-2306. 10.1056/NEJMoa1811744

Discussion & critique

First dedicated SGLT2-inhibitor renal-outcome trial; stopped early for efficacy. Limited to T2DM with macroalbuminuria.